Chasing mendel: Five questions for personalized medicine

Journal of Physiology

Volumn 592, Issue 11, 2014, Pages 2381-2388

  Joyner, Michael J ^a   Prendergast, Franklyn G ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; DISEASES; EVOLUTION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HERITABILITY; HUMAN; HUMAN GENOME PROJECT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT; GENETIC PREDISPOSITION; GENOMICS; GENOTYPE ENVIRONMENT INTERACTION; PHARMACOGENETICS;

GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84901484361     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.272336     Document Type: Review

References (58)

1. Ahmad S, Rukh G, Varga TV, Ali A, Kurbasic A, Shungin D, Ericson U, Koivula RW, Chu AY, Rose LM, Ganna A, Qi Q et al. (2013). Gene×physical activity interactions in obesity: combined analysis of 111, 421 individuals of European ancestry. PLoS Genet 9, e1003607.
2. Aulchenko YS, Struchalin MV, Belonogova NM, Axenovich TI, Weedon MN, Hofman A, Uitterlinden AG, Kayser M, Oostra BA, van Duijn CM, Janssens AC & Borodin PM (2009). Predicting human height by Victorian and genomic methods. Aur J Hum Genet 17, 1070-1075.
3. Baker M (2010). Genomics: The search for association. Nature 467, 1135-1138.
4. Bloss CS, Schork NJ & Topol EJ (2014). Direct-to-consumer pharmacogenomics testing is associated with increased physician utilization. J Med Genet 51, 83-89.
5. Christensen K, Johnson TE & Vaupel JW (2009). The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet 7, 436-448.
6. Cohen JC & Hobbs HH (2013). Genetics. Simple genetics for a complex disease. Science 340, 689-690.
7. Collins FS (2001). Contemplating the end of the beginning. Genome Res 11, 641-643.
8. Comroe JH Jr & Dripps RD (1974). Ben Franklin and open heart surgery. Circ Res 35, 661-669.
9. Crick F (1970). Central dogma of molecular biology. Nature 227, 561-563.
10. Crow JF (2010). Wright and Fisher on inbreeding and random drift. Genetics 184, 609-611.
11. Edwards AW (2011). Mathematizing Darwin. Behav Ecol Sociobiol 65, 421-430.
12. Edwards SL, Beesley J, French JD & Dunning AM (2013). Beyond GWASs: Illuminating the dark road from association to function. Am J Hum Genet 93, 779-797.
13. Fisher RA (1919). The causes of human variability. Eugene Rev 10, 213-220.
14. Forrest DW (1974). Francis Galton: The Life and Work of a Victorian Genius, 340 pp. Taplinger Publishing Co., Inc., New York.
15. Furie B (2013). Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 369, 2345-2346.
16. Ganesh SK, Arnett DK, Assimes TL, Basson CT, Chakravarti A, Ellinor PT, Engler MB, Goldmuntz E, Herrington DM, Hershberger RE, Hong Y, Johnson JA et al. (2013). Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation 128, 2813-2851.
17. Gatenby RA (2009). A change of strategy in the war on cancer. Nature 459, 508-509.
18. Gerstein MB, Bruce C, Rozowsky JS, Zheng D, Du J, Korbel JO, Emanuelsson O, Zhang ZD, Weissman S & Snyder M (2007). What is a gene, post-ENCODE? History and updated definition. Genome Res 17, 669-681.
19. Hanahan D (2014). Rethinking the war on cancer. Lancet 383, 558-563.
20. Hood L (1988). Biotechnology and medicine of the future. JAMA 25, 1837-1844.
21. Hood L & Auffray C (2014). Participatory medicine: a driving force for revolutionizing healthcare. Genome Med 5, 110.
22. Jablonka E (2012). Epigenetic variations in heredity and evolution. Clin Pharmacol Ther 92, 683-688.
23. Johannsen W (1911). The genotype conception of heredity. Am Naturalist XLV, 129-159.
24. Joyner MJ (2011). Why physiology matters in medicine. Physiology 26, 72-75.
25. Kidambi S, Ghosh S, Kotchen JM, Grim CE, Krishnaswami S, Kaldunski ML, Cowley AW Jr, Patel SB & Kotchen TA (2012). Non-replication study of a genome-wide association study for hypertension and blood pressure in African Americans. BMC Med Genet 13, 27.
26. Landstrom AP & Ackerman MJ (2010). Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation 122, 2441-2449.
27. Lennard L, Lilleyman JS, Van Loon J & Weinshilboum RM (1990). Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229.
28. McDermott R (1998). Ethics, epidemiology and the thrifty gene: biological determinism as a health hazard. Soc Sci Med 47, 1189-1195.
29. Mahon F-X (2012). Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012, 122-128.
30. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, Byrne EM, Blackwood DH, Boomsma DI, Cichon S, Heath AC et al. (2013). A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 18, 497-511.
31. Markowitz SM, Park ER, Delahanty LM, O'Brien KE & Grant RW (2011). Perceived impact of diabetes genetic risk testing among patients at high phenotypic risk for type 2 diabetes. Diabetes Care 34, 568-573.
32. Marmot MG & Syme SL (1976). Acculturation and coronary heart disease in Japanese-Americans. Am J Epidemiol 104, 225-247.
33. Minn J, Chiu DT & Wang Y (2013). Variation in the heritability of body mass index based on diverse twin studies: a systematic review. Obes Rev 14, 871-882.
34. Mullard A (2012). Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov 11, 817-819.
35. Müller GB (2007). Evo-devo: extending the evolutionary synthesis. Nat Rev Genet 8, 943-949.
36. Murray CJL, Kulkarni S, Michaud C, Tomijima N, Bulzacchelli MT, Iandiorio TJ & Ezzati M (2006). Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med 3, 1513-1524.
37. New York Times (2013) Bumps in the road to new cholesterol guidelines. http://www.nytimes.com/2013/11/26/health/heart-and-stroke-study-hit-by-a-wave-of-criticism.html
38. Noble D (2011) Differential and integral views of genetics in computational systems biology. Interface Focus 1, 7-15.
39. Noble D (2013). Physiology is rocking the foundations of evolutionary biology. Exp Physiol 98, 1235-1243.
40. Noble D, Jablonka E, Joyner MJ, Müller G & Omholt S (2014). Evolution evolves: physiology returns to centre stage. J Physiol 592, 2237-2244.
41. Omholt SW (2013). From sequence to consequence and back. Prog Biophys Mol Biol 111, 75-82.
42. Pagoto SL & Appelhans BM (2013). A call for an end to the diet debates. JAMA 310, 687-688.
43. Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall V, Selvarai S, Ho N & Cifu A (2013). A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 88, 790-798.
44. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG et al. (2014). CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther, 95, 216-227.
45. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM & Stein EA (2012). Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease inpatients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126, 2408-2417.
46. Rampersaud E, Mitchell BD, Pollin TI, Fu M, Shen H, O'Connell JR, Ducharme JL, Hines S, Sack P, Naglieri R, Shuldiner AR & Snitker S (2008). Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med 168, 1791-1797.
47. Safdar A, Bourgeois JM, Ogborn DI, Little JP, Hettinga BP, Akhtar M, Thompson JE, Melov S, Mocellin NJ, Kujoth GC, Prolla TA & Tarnopolsky MA (2011). Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci U S A 108, 4135-4140.
48. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ et al. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 429-436.
49. Scott SA, Sangkuhl K, Stein CM, Hulot J-S, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA & Shuldiner AR (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94, 317-323.
50. Sebastiani P & Perls TT (2012). The genetics of extreme longevity: lessons from the new England centenarian study. Front Genet 3, 277.
51. Shields R (2011). Common disease: are causative alleles common or rare? PLoS Biol 9, e1001009.
52. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K & Wilson PWF (2013). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.citation.
53. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimaki M & Humphries SE (2010). Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. Br Med J 340, b4838.
54. Vassy JL, O'Brien KE, Waxler JL, Park ER, Delahanty LM, Florez JC, Meigs JB & Grant RW (2012). Impact of literacy and numeracy on motivation for behavior change after diabetes genetic risk testing. Med Decis Making 32, 606-615.
55. Vidal M, Cusick ME & Barabási AL (2011). Interactome networks and human disease. Cell 144, 986-98.
56. Watson J (2013). Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3, 120144.
57. Wilkins A (2011) Why did the modern synthesis give short shrift to 'soft inheritance'? In Transformations of Lamarckism: From Subtle Flids to Molecular Biology, eds Gissis SB & Jablonka E, pp. 127-132. MIT Press, USA.
58. Young JH (2007). Evolution of blood pressure regulation in humans. Curr Hypertens Rep 9, 13-18.